Innovating drug delivery solutions for advanced therapies.
Solving the complexities of formulation, containment and delivery in next generation therapies.
Delivering advanced formulations requires more than innovation - it demands a seamless integration of formulation, device design and scalability. Addressing the challenges like high-viscosity formulations and precision delivery for personalised therapies calls for multidisciplinary expertise. By anticipating bottlenecks early, teams can unlock the full potential of next-generation treatments, improving outcomes and accelerating time to market.
Tackling the challenges of next-generation drug modalities
Next-generation therapies are redefining treatment possibilities - but translating innovation into real-world solutions requires overcoming significant formulation and delivery hurdles. Higher concentration monoclonal antibodies (mAbs) increase potency, viscosity, and delivery volumes beyond current system capacities.
Personalised therapies, like cell, gene, and lipid nanoparticle (LNP) treatments, require precise handling, while particulate suspensions demand advanced resuspension and delivery techniques.
Success demands expertise in fluid dynamics, dosing strategies, and patient-focused design.
Breaking boundaries - from targeting tumours to crossing the blood-brain barrier
Beyond formulation and viscosity challenges, many advanced therapies require precise targeting - whether to attack tumours, cross the blood-brain barrier, or modulate immune response. Overcoming these biological barriers is key to unlocking their full potential.
But how can we achieve precision and scale in delivering complex biologics?
Advanced therapies hold immense potential for oncology, regenerative medicine, and beyond. But their success depends on overcoming hurdles in precision targeting, immune response, and scalability. Cutting-edge delivery strategies - like encapsulation and nanoparticle engineering - are enabling more targeted, efficient, and scalable solutions. By optimising delivery routes and overcoming biological barriers, these breakthroughs are unlocking new possibilities in patient treatment.
Discover the latest innovations shaping the future of advanced therapies.
Meet us at
Room-temperature mRNA: unlocking global access
While precision targeting is crucial for many therapies, others face a different challenge: stability and accessibility. Nowhere is this more evident than in mRNA-based treatments, where cold storage has long been a limiting factor. But what if we could change that?
mRNA vaccines have transformed global health, but ultra-cold storage is still a major barrier to accessibility. What if mRNA vaccines and therapeutics could be stored and delivered at room temperature?
At TTP, we’ve developed a breakthrough vacuum-spray drying process to create dry powder mRNA formulations that remain stable at room temperature, eliminating the need for costly refrigeration.
Beyond vaccines, this technology enables inhaled mRNA therapeutics, offering enhanced protection against respiratory infections and targeted treatments for lung diseases.
Unlike traditional freeze-drying and spray-drying methods, our approach minimises damage to lipid nanoparticles, ensuring stability and scalability. From personalised cancer vaccines to mass immunisation, room-temperature mRNA unlocks new possibilities for global healthcare.
Read the latest insight on room temperature-stable mRNAs.
Engineering the future of drug delivery at TTP
From blank sheet to clinical reality, TTP's Drug Delivery team creates groundbreaking solutions to solve the toughest drug delivery challenges .Our proven capabilities in fluid modelling, material science, human factors and device development enable scalable, next-generation drug delivery solutions, empowering transformative outcomes in patient care.
Below we delve deeper into these critical topics - exploring the challenges, uncovering new insights, and sharing strategies to advance drug delivery technologies for the therapies of tomorrow.
Find out how TTP's Drug Delivery product development team can support your technology ambitions.
.avif)
When we received the new moulded parts incorporating TTP’s recommendations, all of them performed as intended and within specification. We were really excited.
Justin Creel
Vice President of Device Development
TTP have been an invaluable long-term partner for AstraZeneca. They have both the deep expertise and creativity to generate innovative concepts, and the horsepower to accelerate these through design verification.
Dan Deaton
Executive Director, Patient Experience & Innovation at AstraZeneca
TTP has been an incredible partner, complementing our expertise and delivering designs from white board to moulded functional prototypes. With TTP’s support, Achilles is scaling our manufacturing process and bringing transformative therapies from bench to bedside. The TTP team has shown the same level of excitement as us in getting these therapies to the people who need them.
Ed Samuel
EVP Technical Operations
Our areas of focus:
Medical Devices & Drug Delivery
Our approach and capabilities
We deliver across the entire life of a project, from opportunity discovery to production engineering. Discover how our interdisciplinary teams of experts collaborate to tackle the toughest product development challenges.
Our campus and facilities
Our award-winning campus has been designed with a clear vision. To create space which can suport our people and our clients as we develop and deliver the very best technology solution.
Software capability at TTP
Engaged in all stages of software and product development, our software capability at TTP covers the full spectrum—from in-depth analysis and system architecture to prototype design, implementation, and test development.
Manufacturing capability at TTP
Working seamlessly with our development teams, we take clients' products through prototype builds, clinical trials, pilot manufacture and more. Using TTP Manufacturing reduces uncertainty, risk and time to market for our clients.
Meet some of the team
Harry Bullivant
Matthew Parker
Svilen Savov
